Bayer shares surge after US Supreme Court clears glyphosate liability

On 25 June 2026 the US Supreme Court ruled 7‑2 in favor of Bayer and Monsanto, holding that EPA regulations pre‑empt state lawsuits over Roundup’s glyphosate. The decision removed the legal basis for many cancer‑warning claims against Bayer, paving the way for a potential $7.25 billion settlement.

Following the ruling, Bayer’s stock jumped almost 20 % in a single session, propelling the share price from around €25 to above €50 and delivering an 80.99 % gain over the past twelve months. Analysts note the rally marks a dramatic turnaround for a company long weighed down by litigation costs and debt from the 2018 Monsanto acquisition.

The surge has now given way to a consolidation phase, with the share price stabilising near €50 and technical indicators signalling over‑bought conditions. Thousands of lawsuits remain pending—about 4,000 at the federal level and tens of thousands in individual US states—so further legal developments could still affect the stock.